British Biotech Defends Decision Not To Disclose DDMAC Letter
Executive Summary
British Biotech believes that it was not required to disclose receipt of a Notice of Violation letter from FDA's Division of Drug Marketing, Advertising and Communications, the company said in a May 19 "Circular to Shareholders."